NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.

@article{Shibata2011NRF2MC,
  title={NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.},
  author={Tatsuhiro Shibata and Akiko Kokubu and Shigeru Saito and Mako Narisawa-Saito and Hiroki Sasaki and Kazuhiko Aoyagi and Yuki Yoshimatsu and Yuji Tachimori and Ryoji Kushima and Tohru Kiyono and Masayuki Yamamoto},
  journal={Neoplasia},
  year={2011},
  volume={13 9},
  pages={864-73}
}
Esophageal squamous cancer (ESC) is one of the most aggressive tumors of the gastrointestinal tract. A combination of chemotherapy and radiation therapy (CRT) has improved the clinical outcome, but the molecular background determining the effectiveness of therapy remains unknown. NRF2 is a master transcriptional regulator of stress adaptation, and gain of-function mutation of NRF2 in cancer confers resistance to stressors including anticancer therapy. Direct resequencing analysis revealed that… CONTINUE READING

From This Paper

Topics from this paper.
58 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

Similar Papers

Loading similar papers…